Table 5.
Efficacy endpoints
| Endpoint | (n = 245 patients)*† |
|---|---|
| Number of patients required repeat droperidol dose | 67/245 (27.3) |
|
Use of concomitant rescue medications within 4 h of first droperidol administration# | |
| Acute agitation (n = 61) | 21/61 (34) |
| Headache (n = 5) | 1/5 (20) |
| Nausea/vomiting (n = 122) | 16/122 (13.1) |
| CHS (n = 64) | 28/ 64 (43.7) |
| Abdominal pain (n = 86) | 38/86 (44.1) |
| Time to first rescue medications after droperidol, minutes | 138 [55.5-208.5] |
| Disposition | |
| Floor | 60 (24.4) |
| ICU | 17 (6.9) |
| Home | 77 (31.4) |
| Facility | 14 (4.2) |
| Time from admission to discharge from the ED, minutes | 543 [363-1062.5] |
| Time from droperidol administration to discharge from the ED, minutes | 412 [211-816.2] |
*data expressed as median [IQR], †data expressed as n (%)
#some patients had more than one indication
Abbreviations: CHS, cannabinoid hyperemesis syndrome; ICU, intensive care unit